Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

PXSL.O

ISIN: US71715J1051
SEDOL: B01Z8T8

Rating:

BUY

Target Price:

23.54 USD

Investment Horizon:

6 to 24 months
20th Nov 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Pharmaxis Ltd.’s (Pharmaxis) common stock experienced a significant decline of 25.1% since our 1Q 09 update report, dated 21 October 2008, due to rising investor concerns over the weakening US economy and its repercussions on other economies. However, our fundamental outlook for the company remains unchanged and, hence, we reiterate our BUY rating for the common stock. We reiterate the ADR a BUY rating as we continue to anticipate…

21st Oct 2008 View Report   Download

1Q 09 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

Pharmaxis Ltd. (Pharmaxis) reported strong y-o-y revenue growth, primarily driven by strong sales of Aridol in 1Q 09. However, the company recorded y-o-y increase in losses at the operating and net levels, higher than our expectations, primarily due to higher than anticipated commercial and Research and Development (R&D;) expenses. Going forward, we expect Aridol to support revenue growth…

15th Oct 2008 View Report   Download

1Q 09 News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Pharmaxis Limited (Pharmaxis) reported strong y-o-y growth in revenues in 1Q 09, primarily associated with improved Aridol sales during the quarter. However, 1Q 09 revenues were below our estimate due to delay in the launch of Aridol in Spain and France due to the lengthy approval process....

15th Sep 2008 View Report   Download

4Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

Pharmaxis’ top-line growth was boosted by robust growth in Aridol sales in 4Q 08. Pharmaxis is launching its flagship brands in multiple countries, which supports our optimism for top-line growth, going forward....

21st Aug 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Pharmaxis Limited (Pharmaxis), on 19 August 2008, announced the completion of a Phase III clinical trial of Bronchitol for the treatment of bronchiectasis. According to the company, the Phase III clinical trials have concluded with no serious adverse effects on patients suffering from Bronchietasis after 12 months of therapy. Pharmaxis is expected to file for marketing approval in Australia after the encouraging clinical results....